Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Lung function
[25] Systematic review	Adults with acute asthma 2 RCTs in this analysis	Forced expiratory volume in 1 second (FEV1) 60 minutes with adding nebulised magnesium sulfate to beta2 agonists with beta2 agonists alone Absolute results not reported	SMD +0.18 95% CI –0.65 to +1.02 P = 0.67 Statistically significant heterogeneity present in analysis (I2 = 81%, P = 0.002)		Not significant
[25] Systematic review	People with acute asthma 2 RCTs in this analysis	Peak expiratory flow up to 60 minutes with adding nebulised magnesium sulfate to beta2 agonists with beta2 agonists alone Absolute results not reported	SMD +7.07 95% CI –11.69 to +25.84 P = 0.46		Not significant
[25] Systematic review	Adults with acute asthma 2 RCTs in this analysis	Peak expiratory flow discharge with adding nebulised magnesium sulfate to beta2 agonists with beta2 agonists alone Absolute results not reported	SMD +0.68 95% CI –8.56 to +9.92 P = 0.89		Not significant
[25] Systematic review	Adults with severe asthma (FEV1 or PEFR <50% predicted) Data from 1 RCT Subgroup analysis	Forced expiratory volume at 1 second with adding nebulised magnesium sulfate to beta2 agonists with beta2 agonists alone Absolute results not reported	SMD 0.63 95% CI 0.07 to 1.19 P = 0.028	Effect size not calculated	adding nebulised magnesium sulfate to beta2 agonists